Global Amyotrophic Lateral Sclerosis (ALS) Treatment Drug Competitive Landscape Professional Research Report 2024

Global Amyotrophic Lateral Sclerosis (ALS) Treatment Drug Competitive Landscape Professional Research Report 2024

Research Summary

There is currently no known cure for ALS, but there are certain drugs used in the treatment of ALS that can help slow down the progression of the disease and relieve some of the symptoms. Some of the ALS treatment drugs include: 1. Riluzole: This is the only FDA-approved drug for the treatment of ALS. It helps to slow down the progression of the disease by reducing the levels of a neurotransmitter called glutamate. 2. Edaravone: This is another FDA-approved drug that is used to treat ALS. It works by reducing the damage caused by oxidative stress to nerve cells. 3. Baclofen: This is a muscle relaxant that is used to relieve muscle stiffness and spasms in people with ALS. 4. Gabapentin: This is an anticonvulsant drug that can be used to treat pain and muscle spasms in people with ALS. 5. Dextromethorphan: This is a cough suppressant that can be used to treat the excessive saliva production and coughing that occurs in people with ALS.

According to DIResearch's in-depth investigation and research, the global Amyotrophic Lateral Sclerosis (ALS) Treatment Drug market size will reach XX US$ Million in 2024, and is expected to reach XX US$ Million in 2030, with a CAGR of XX% (2025-2030). Among them, the China market has changed rapidly in the past few years. The market size in 2024 will be XX US$ Million, accounting for approximately XX% of the world. It is expected to reach XX US$ Million in 2030, and the global share will reach XX%.

The major global manufacturers of Amyotrophic Lateral Sclerosis (ALS) Treatment Drug include Mitsubishi Tanabe Pharma, Sanofi, Mylan Pharma, Apotex, Glemark Generics, Covis Pharma, Sun Pharma, Lunan Pharma etc. The global players competition landscape in this report is divided into three tiers. The first tiers is the global leading enterprise, which occupies a major market share, is in a leading position in the industry, has strong competitiveness and influence, and has a large revenue scale; the second tiers has a certain share and popularity in the market, actively follows the industry leaders in product, service or technological innovation, and has a medium revenue scale; the third tiers has a smaller share in the market, has a lower brand awareness, mainly focuses on the local market, and has a relatively small revenue scale.

This report studies the market size, price trends and future development prospects of Amyotrophic Lateral Sclerosis (ALS) Treatment Drug. Focus on analysing the market share, product portfolio, revenue and gross profit margin of global major manufacturers, as well as the market status and trends of different product types and applications in the global Amyotrophic Lateral Sclerosis (ALS) Treatment Drug market. The report data covers historical data from 2019 to 2023, base year in 2024 and forecast data from 2025 to 2030.

The regions and countries in the report include North America, Europe, China, APAC (excl. China), Latin America and Middle East and Africa, covering the Amyotrophic Lateral Sclerosis (ALS) Treatment Drug market conditions and future development trends of key regions and countries, combined with industry-related policies and the latest technological developments, analyze the development characteristics of Amyotrophic Lateral Sclerosis (ALS) Treatment Drug industries in various regions and countries, help companies understand the development characteristics of each region, help companies formulate business strategies, and achieve the ultimate goal of the company's global development strategy.

The data sources of this report mainly include the National Bureau of Statistics, customs databases, industry associations, corporate financial reports, third-party databases, etc. Among them, macroeconomic data mainly comes from the National Bureau of Statistics, International Economic Research Organization; industry statistical data mainly come from industry associations; company data mainly comes from interviews, public information collection, third-party reliable databases, and price data mainly comes from various markets monitoring database.

Global Key Manufacturers of Amyotrophic Lateral Sclerosis (ALS) Treatment Drug Include:

Mitsubishi Tanabe Pharma

Sanofi

Mylan Pharma

Apotex

Glemark Generics

Covis Pharma

Sun Pharma

Lunan Pharma

Amyotrophic Lateral Sclerosis (ALS) Treatment Drug Product Segment Include:

Riluzole

Edaravone (Radicava)

Other

Amyotrophic Lateral Sclerosis (ALS) Treatment Drug Product Application Include:

Hospital

Drugs Store

Other

Chapter Scope

Chapter 1: Product Research Range, Product Types and Applications, Market Overview, Market Situation and Trends

Chapter 2: Global Amyotrophic Lateral Sclerosis (ALS) Treatment Drug Industry PESTEL Analysis

Chapter 3: Global Amyotrophic Lateral Sclerosis (ALS) Treatment Drug Industry Porter’s Five Forces Analysis

Chapter 4: Global Amyotrophic Lateral Sclerosis (ALS) Treatment Drug Major Regional Market Size and Forecast Analysis

Chapter 5: Global Amyotrophic Lateral Sclerosis (ALS) Treatment Drug Market Size and Forecast by Type and Application Analysis

Chapter 6: North America Amyotrophic Lateral Sclerosis (ALS) Treatment Drug Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 7: Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Drug Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 8: China Amyotrophic Lateral Sclerosis (ALS) Treatment Drug Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 9: APAC (Excl. China) Amyotrophic Lateral Sclerosis (ALS) Treatment Drug Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 10: Latin America Amyotrophic Lateral Sclerosis (ALS) Treatment Drug Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 11: Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Drug Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 12: Global Amyotrophic Lateral Sclerosis (ALS) Treatment Drug Competitive Analysis of Key Manufacturers (Revenue, Market Share, Regional Distribution and Industry Concentration)

Chapter 13: Key Company Profiles (Product Portfolio, Revenue and Gross Margin)

Chapter 14: Industrial Chain Analysis, Include Raw Material Suppliers, Distributors and Customers

Chapter 15: Research Findings and Conclusion

Chapter 16: Methodology and Data Sources